Thelansis

Duchenne Muscular Dystrophy (DMD) Market Outlook Thelansis’s “Duchenne Muscular Dystrophy (DMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Duchenne Muscular Dystrophy (DMD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest ...

  Duchenne Muscular Dystrophy (DMD) Market Outlook Thelansis’s “Duchenne Muscular Dystrophy (DMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Duchenne Muscular Dystrophy (DMD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Duchenne Muscular Dystrophy (DMD) Overview Duchenne muscular dystrophy (DMD) is a rare genetic disorder characterized by the progressive weakening and wasting of muscles, affecting skeletal, smooth, and cardiac muscle tissues. The underlying cause of muscle damage is the absence of the sarcolemmal protein dystrophin due to variations in the DMD gene located on Xp21.2. Symptoms of DMD typically manifest i...

 Duchenne muscular dystrophy (DMD) is a rare genetic disorder characterized by the progressive weakening and wasting of muscles, affecting skeletal, smooth, and cardiac muscle tissues. The underlying cause of muscle damage is the absence of the sarcolemmal protein dystrophin due to variations in the DMD gene located on Xp21.2. Symptoms of DMD typically manifest in early childhood, with affected boys often experiencing delayed walking, typically after 18 months, along with speech and developmental delays. Individuals with DMD may also face autism and behavioral issues, including ADHD, anxiety, and obsessive-compulsive disorder. Unfortunately, untreated children with DMD rarely achieve the ability to run or jump. The condition progresses rapidly, leading to a characteristic waddling gait and a positive Gowers' sign. Climbing stairs becomes challenging, and frequent falls occur. Independent walking is typically lost between the ages of 6 and 13, with an average age of 9.5 in non-stero...

  Duchenne muscular dystrophy (DMD) is caused by a lack of dystrophin, a protein that aids in the maintenance of muscle cells. Symptoms usually appear in early childhood, between the ages of 3 and 5. The disease primarily affects boys but can also affect girls in rare cases. Because the gene that can carry a DMD-causing mutation is on the X chromosome, DMD is inherited in an X-linked pattern. Mutations in the DMD gene cause progressive muscle weakness, loss of independent ambulation by early adolescence, and premature death from cardiorespiratory complications. The global DMD prevalence was 7.1 cases per 100,000 males and 2.8 cases per 100,000 in the general population, while the global DMD birth prevalence was 19.8 per 100,000 live male births. Thelansis’s “Duchenne Muscular Dystrophy (DMD) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription shar...

Duchenne muscular dystrophy (DMD) are a group of genetic conditions characterized by progressive muscle weakness and wasting (atrophy). Etiology- DMD is caused by mutations of the DMD gene located on the short arm (p) of the X chromosome (Xp21.2). The DMD gene regulates (encodes for) the production of dystrophin, a protein that appears to play an essential role in maintaining the integrity of cell membrane in skeletal (voluntary) and cardiac muscle cells Epidemiology- Affecting approximately 1 in 3,500 male births worldwide and estimated to affect 250,000 individuals in the United States.   The competitive landscape of Duchenne muscular dystrophy (DMD) includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary. KOLs insights of Duchenne muscular dystrophy (DMD) across 8 MM market from the center of Excellence/ Public/ Private hospitals particip...